Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen

Biochemical Pharmacology

Volumn 55, Issue 4, 1998, Pages 523-531

  Cheng, Ann Lli ^a,b   Chuang, Shuang En ^a,b   Fine, Robert L ^c   Yeh, Kun Huei ^a,b   Liao, Chao Ming ^a   Lay, Jong Ding ^a   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c College of physicians and surgeons of columbia university ^*  (United States)

Author keywords

Apoptosis; Chemotherapy; Hepatocellular carcinoma; Protein kinase C; Tamoxifen

Indexed keywords

CARRIER PROTEIN; DOXORUBICIN; PROTEIN KINASE C; TAMOXIFEN; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOLOGICAL TRANSPORT, ACTIVE; DOXORUBICIN; DRUG RESISTANCE; DRUG SYNERGISM; ENZYME ACTIVATION; FLUORESCENT DYES; HUMANS; ISOENZYMES; LIVER NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE C; RAS PROTEINS; RHODAMINE 123; RHODAMINES; TAMOXIFEN; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0032519653     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00594-7     Document Type: Article

References (45)

1. Lotze MT, Flickinger JC and Carr BJ, Hepatobiliary system. In: Cancer: Principles and Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 883-914. J.B. Lippincott, Philadelphia, 1993.
2. Nerenstone SR, Ihde DC and Friedman MA, Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 15: 1-31, 1988.
3. Huang C, Wu M, Xu G, Li D, Chen H, Tu Z, Jiang H and Gu J, Overexpression of the MDR-1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264, 1992.
4. Berman E, Adams M, Duiguo-Osterndorf R, Godfrey L, Clarkson B and Andreeff M, Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818-825, 1991.
5. Kang Y and Perry R, Modulatory effects of tamoxifen and recombinant human α-interferon on doxorubicin resistance. Cancer Res 53: 3040-3045, 1993.
6. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL and Carmichael J, Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67: 1189-1195, 1993.
7. Cheng AL, Yeh KH, Fine RL, Chuang SE, Yang CH, Wang LH and Chen DS, Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology, in press.
8. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC and Fine RL, High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816, 1992.
9. Melia WM, Jonhson PJ and Williams R, Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71: 1213-1216, 1987.
10. O'Brian CA, Liskamp RM, Solomon DH and Weinstein IB, Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465, 1985.
11. Doong SL, Ho KG, Fisher MH and Cheng YC, In vitro sensitivity to anticancer drugs and the expression of the pleiotropic drug resistant biochemical determinants of human hepatoma cell lines. Proc Am Assoc Cancer Res 31: 365, 1990.
12. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB, Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
13. Chou TC and Talalay P, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
14. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W and Kalden JR, A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22: 5506-5507, 1994.
15. Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z, The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53: 3186-3192, 1993.
16. Pu Y-S, Hsieh T-S, Cheng A-L, Tseng N-F, Su I-J, Hsieh C-Y, Lai M-K and Tsai T-C, Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy. Br J Urol 77: 76-85, 1996.
17. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA, Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC α. J Biol Chem 268: 658-664, 1993.
18. Szallasi Z, Smith CB and Blumberg PM, Dissociation of phorbol esters leads to immediate redistribution to the cytosol of protein kinase Cα and Cδ in mouse keratinocytes. J Biol Chem 269: 27159-27162, 1994.
19. 1 pathways. Proc Natl Acad Sci USA 92: 4793-4797, 1995.
20. Basu A and Weixel KM, Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int J Cancer 62: 457-460, 1995.
21. Lam HYP, Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118: 27-32, 1984.
22. Huynh HT, Tetenes E, Wallace L and Pollak M, In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727-1730, 1993.
23. Noguchi S, Motomura K, Inaji H, Imalka S and Koyama H, Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer 72: 131-136, 1993.
24. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992.
25. Baral E, Nagy E and Berczi I, Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 75: 591-599, 1995.
26. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I and Weiss MH, Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994.
27. Gelmann EP, Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog. J Natl Cancer Inst 88: 224-226, 1996.
28. Clarke R, Van den Berg HW and Murphy RF, Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17β-estradiol. J Natl Cancer Inst 82: 1702-1705, 1990.
29. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ and LeMarbre P, Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403-1405, 1984.
30. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E and Costa P, Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327: 516-523, 1992.
31. Vertosick FT, Selker RG, Pollack IF and Arena V, The treatment of intracranial malignant glioma using orally administered tamoxifen therapy: Preliminary results in a series of "failed" patients. Neurosurgery 30: 897-903, 1992.
32. Narasimhan P, Tamoxifen in the treatment of refractory lymphoma. N Engl J Med 311: 1258-1259, 1984.
33. Kang Y, Cortina R and Perry RR, Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 88: 279-284, 1996.
34. Berman E, McBride M, Lin S, Menedeq-Bodet C and Tong W, Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9: 1631-1637, 1995.
35. Jiang SY, Shyu RY, Yeh MY and Jordan VC, Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 23: 712-719, 1995.
36. Nakadate T, Jeng AY and Blumberg PM, Comparison of protein kinase C functional assay to clarify mechanisms of inhibitor action. Biochem Pharmacol 37: 1541-1545, 1988.
37. Rochefort H, Nonsteroidal antiestrogens are estrogen-receptor-targeted growth inhibitors that can act in the absence of estrogens. Horm Res 28: 196-201, 1987.
38. Laredo J, Huynh A, Muller C, Jaffrézou JP, Bailly JD, Cassar G, Laurent G and Demur C, Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood 84: 229-237, 1994.
39. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganxo F Jr, Kelsen DP, Fuks Z and Albino AP, Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 87: 1394-1399, 1995.
40. Sachs CW, Safa AR, Harrison SD and Fine RL, Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639-26648, 1995.
41. Ponnathpur V, Ibrado AM, Reed JC, Ray Y, Huang Y, Self S, Bullock G, Nawabi A and Bhalla K, Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26Bcl-2 protein. Clin Cancer Res 1: 1399-1406, 1995.
42. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR and Grant S, Effects of bryostatin 1 and other pharmacological activators of protein kinase C on l-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 839-852, 1994.
43. Grunicke HH and Überall F, Protein kinase C modulation. Sem Cancer Biol 3: 351-360, 1992.
44. Weinstein IB, Protein kinase C and signal transduction: A role in cancer prevention and treatment? Adv Oncol 9: 3-9, 1994.
45. Raffo AJ and Fine RL, Tamoxifen and cisplatin induce BAX mRNA in human melanoma cells. Proc Am Assoc Cancer Res 37: 414, 1996.